Begin with what you feel.

Why Millions Are Already Using These Compounds

Several million American adults currently source peptides through research-chemical channels and overseas suppliers. That is not a fringe number. It is a population larger than the prescription user base of most mid-tier pharmaceuticals.

Domestic access was narrowed by FDA Section 503A compounding actions that moved BPC-157, CJC-1295, Ipamorelin, MOTS-c, and more than a dozen other peptides off the bulk-compounding allowable list between 2020 and 2024. The move was made despite decades of international clinical use and no recorded population-level harm signal. Concurrent pressure on 503B outsourcing facilities closed the remaining legitimate domestic supply. Comparable compounds remain in active prescriber use across Europe, Asia, Latin America, and the Gulf.

The regulatory capture pattern is structural, not incidental. Pharmaceutical industry user fees fund a majority of the FDA drug-review budget. Senior reviewers rotate into industry. State medical and pharmacy boards are staffed disproportionately by members with institutional ties to the same industry. The outcome is predictable: compounds with decades of human use and strong mechanism data are pushed to the gray market while patent-protected analogs move through approval.

The practical result. Tens of millions of adults are self-administering without quality verification, without physician context, without recourse. The peptides listed below are the compounds they are already using. Pivotal's position is not that the market is illegitimate. Our position is that the underserved population is real, their need is real, and a private, physician-adjacent intelligence layer is the correction.

This page exists because the alternative is a self-administering public operating from forum posts and anonymous sellers.